Hermansky-Pudlak syndrome type 8

Hermansky-Pudlak syndrome type 8 (HPS-8) is an extremely rare autosomal recessive disorder belonging to the group of Hermansky-Pudlak syndromes, which are characterized by defects in the biogenesis of lysosome-related organelles. HPS-8 is caused by biallelic pathogenic variants in the BLOC1S3 gene (also known as BLOS3), which encodes a subunit of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). This complex plays a critical role in the proper formation and trafficking of lysosome-related organelles, including melanosomes in melanocytes and dense granules in platelets. As with other forms of Hermansky-Pudlak syndrome, HPS-8 primarily affects the skin, eyes, and blood. Key clinical features include oculocutaneous albinism (reduced pigmentation of the skin, hair, and eyes), visual impairment due to foveal hypoplasia and nystagmus, and a bleeding diathesis resulting from platelet storage pool deficiency (absence or reduction of platelet dense granules). Patients may experience prolonged bleeding times, easy bruising, and excessive bleeding following surgery or dental procedures. The degree of hypopigmentation can vary among affected individuals. HPS-8 is one of the rarest subtypes of Hermansky-Pudlak syndrome, with very few cases reported in the medical literature. Unlike some other HPS subtypes (particularly HPS-1 and HPS-4), HPS-8 has not been clearly associated with pulmonary fibrosis or granulomatous colitis, though long-term data are limited due to the rarity of the condition. There is currently no cure for HPS-8. Management is supportive and includes sun protection, regular ophthalmologic evaluations, visual aids, and precautions to manage bleeding risk. Desmopressin (DDAVP) or platelet transfusions may be used to control bleeding episodes. Patients should avoid medications that impair platelet function, such as aspirin and nonsteroidal anti-inflammatory drugs.

Common questions about Hermansky-Pudlak syndrome type 8